Appendix 4E and Audited 2016 Financial Report
Filed with ASX · · 69 pages · English
Earlier from Argent Biopharma
- Psoriasis and Acne Tests Advancing Ahead of Product Launch
- Sale of Lingokoto and Bouroubourou Gold Exploration Assets
- Leading Epilepsy Expert Joins MXC Strategic Advisory Board
- First Revenues Received from Californian Cosmetics Deal
- MXCs First Crops Planted at European CBD Production Farm
Later from Argent Biopharma
- Strategic Agreement signed with Epilepsy Action Australia
- New Med Cannabis White Paper Developed with Uni of Sydney
- Operations Update - Multiple Revenue Streams Imminent
- September Quarter Activity and Cashflow Report
- EU Registration Commenced for CBD Derma Product Sales
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma